Last edition
News about "Celltrion"
US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Celltrion | 04/11/2025 | By Dineshwori
FDA Expands Indications for Celltrion's YUFLYMA to Include Pediatric and Adolescent Patients
Celltrion has announced that the US Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA (adalimumab-aaty) and its unbranded version to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older.
Celltrion | 17/10/2025 | By Dineshwori | 211
Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT
Celltrion has received approval from the US Food and Drug Administration (FDA) for EYDENZELT (aflibercept-boav), a biosimilar to EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Celltrion | 11/10/2025 | By Dineshwori | 151
Hikma, Celltrion Deepen Ties to Boost Biosimilar Access in Middle East and North Africa
British multinational pharmaceutical company Hikma Pharmaceuticals has signed new exclusive licensing agreements with its long-standing partner, South Korea’s Celltrion, covering the Middle East and North Africa (MENA) region.
Celltrion | 06/10/2025 | By Dineshwori | 175
Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market
AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).
Celltrion | 03/10/2025 | By Dineshwori | 191
Prometheus Laboratories Collaborates with Celltrion for Anser Testing
Prometheus is the first specialty lab to validate TDM testing for both intravenous and subcutaneous infliximab, supporting the growing demand for at-home treatment options.
Celltrion | 28/08/2025 | By Dineshwori
Celltrion Secures US FDA Approval for Expanded Indication for AVTOZMA
Celltrion has received FDA approval for an expanded indication of AVTOZMA IV (tocilizumab-anoh) to treat cytokine release syndrome (CRS), achieving full indication parity with reference biologic ACTEMRA IV in the US.
Celltrion | 07/08/2025 | By Mrinmoy Dey | 101
Celltrion to Acquire US Biologics Plant to Counter Potential Pharma Tariffs
Celltrion has been selected as the preferred bidder to acquire a large biologics manufacturing plant in the United States —a strategic move aimed at insulating the company from potential US pharmaceutical tariffs.
Celltrion | 30/07/2025 | By Dineshwori | 383
Celltrion Announces Three-Stage Strategy to Counter Trump's Pharma Tariff Plan
Celltrion has announced its response strategy to US President Donald Trump’s plan to impose tariffs on pharmaceuticals.
Celltrion | 10/07/2025 | By Dineshwori | 407
Celltrion's YUFLYMA Achieves FDA Interchangeable Status
YUFLYMA is an FDA-approved, high-concentration (100mg/mL) and citrate-free formulation of Humira® biosimilar, approved for multiple inflammatory indications.
Celltrion | 15/04/2025 | By Abha | 290
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy